deCODE genetics: A sequence variant that increases risk of pregnancy loss
- None.
- None.
Insights
The discovery of a genetic variant in the SYCE2 gene that increases the risk of pregnancy loss by 22% represents a significant advancement in reproductive genetics. The implications of this discovery are multifaceted. For one, it provides a clearer understanding of the biological mechanisms behind pregnancy loss, which is crucial for developing diagnostic tools and potential therapeutic interventions. The identification of this variant also paves the way for personalized medicine approaches where individuals at higher risk can be counseled accordingly.
From a medical research perspective, the study's findings could stimulate further research into the SYCE2 gene and its role in meiosis, particularly the stability of the synaptonemal complex. The potential to develop targeted therapies or preventative measures could be explored, which would be of immense value to individuals facing recurrent pregnancy losses. Additionally, this research highlights the importance of genetic screening in reproductive health, potentially influencing clinical practices and guidelines in the future.
As a geneticist, the reported association between the SYCE2 gene variant and pregnancy loss is particularly intriguing due to the variant's influence on chromosomal recombination. Recombination is a fundamental biological process and disruptions can lead to a range of developmental issues. The study's findings that the variant affects the positioning of crossovers during meiosis, with a proportional relationship to chromosome length, adds a new layer to our understanding of chromosomal behavior and its impact on fertility.
Furthermore, the fact that this variant is maintained in the population despite its detrimental effect on pregnancy success raises questions about its evolutionary significance. It is possible that this variant confers some unknown advantage that outweighs the reproductive cost, or it may be linked to other beneficial genetic factors. This discovery opens new research avenues into the evolutionary dynamics of genetic variants with negative reproductive outcomes.
The announcement by deCODE genetics, a subsidiary of Amgen, concerning the genetic variant associated with pregnancy loss has potential implications for the biotech market. This kind of genetic research is at the forefront of personalized medicine, a rapidly growing sector within the healthcare industry. As personalized healthcare solutions become more prevalent, companies like Amgen could see increased demand for genetic testing and tailored treatments, which could positively impact their market position and financial performance.
Investors may view this development as an indicator of Amgen's commitment to innovative research, which could strengthen the company's image as a leader in the biotech industry. However, the translation of this research into marketable products or services will require further development and regulatory approval, which can be a lengthy and uncertain process. Stakeholders should consider the long-term potential of such discoveries against the backdrop of the company's overall research pipeline and market strategy.
While it is well established that chromosomal abnormalities are a major cause of miscarriages the biology behind pregnancy losses with or without chromosomal errors is not well understood. Over 114 thousand women from
In a previous report by deCODE scientists this missense variant was shown to associate with recombination phenotypes in chromosomes that were transmitted from the mother. Recombination between homologous chromosomes is an essential part of meiosis, the generation of the human egg and sperm cell. The product of SYCE2 forms a part of a protein complex that is essential for the alignment of homologous chromosomes for recombination and the missense variant associated with pregnancy loss and recombination is predicted to affect the stability of this protein complex.
A closer inspection of the effect of the variant on recombination revealed an effect on the positioning of crossovers that is proportional to the length of the chromosomes, the longer the chromosome the larger the effect. The effect on recombination is measured in live-born individuals. The authors propose that this effect may be more extreme in pregnancies that are lost and may contribute to pregnancy loss. The association with pregnancy loss does not account for embryos lost in early gestation before pregnancy has been detected so the effect of the variant on pregnancy success may be underestimated.
The findings reported in this study demonstrate that a variant with a substantial effect on recombinations can be maintained in the population despite increasing the risk of pregnancy loss.
Based in
Photo: https://mma.prnewswire.com/media/2326042/Valgerdur_Steinthorsdottir.jpg
Logo: https://mma.prnewswire.com/media/1535464/deCODE_genetics_Amgen_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/decode-genetics-a-sequence-variant-that-increases-risk-of-pregnancy-loss-302043584.html
SOURCE deCODE genetics
FAQ
What is the title of the study published by deCODE genetics?
What is the name of the gene associated with an increased risk of pregnancy loss?
How many women participated in the genome-wide association study?
What is the percentage increase in the risk of pregnancy loss associated with the missense variant in the SYCE2 gene?
What is the role of the SYCE2 gene in recombination?
What is the effect of the variant on the positioning of crossovers during recombination?
What is the potential impact of the variant on pregnancy loss?
What does the study reveal about the maintenance of the variant in the population?
What is the relationship between deCODE genetics and Amgen?
